Sanofi-Aventis Deutschland GMBH v. Mylan


Wilson Sonsini Goodrich & Rosati advised Mylan in the dispute, Weil, Gotshal & Manges advised Sanofi-Aventis.

U.S. Court of Appeals for the Federal Circuit invalidated two Sanofi patents relating to Sanofi’s Lantus vial product, upholding December 2018 decisions from the Patent Trial and Appeal Board (PTAB). In a 2-1 opinion, the majority determined that the PTAB’s findings were detailed and well supported by substantial evidence. The Federal Circuit’s decision clears the legal hurdle towards marketing of Mylan’s proposed insulin glargine vial product.

Lantus is a prescription medicine used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar, with the vial product having sales of approximately $1.82B for the 12 months ending September 30, 2019. The two formulation patents had been set to expire in 2023.

Wilson Sonsini advised Mylan with Doug Carsten (Picture), Jeff Guise, Ellie Steiner, Rick Torczon, Lori Westin, Lora Green, Art Dykhuis, Alina Litoshyk, and Adam Burrowbridge.

Weil, Gotshal & Manges advised Sanofi-Aventis with Adam B. Banks, Elizabeth S. Weiswasser, Anish Desai, Andrew Peter Gesior, Aaron L. J. Pereira and Robert T. Vlasis.

Involved fees earner: Adam Banks – Weil, Gotshal & Manges; Anish Desai – Weil, Gotshal & Manges; Andrew Peter Gesior – Weil, Gotshal & Manges; Aaron Pereira – Weil, Gotshal & Manges; Robert Vlasis – Weil, Gotshal & Manges; Elizabeth Weiswasser – Weil, Gotshal & Manges; Adam Burrowbridge – Wilson Sonsini Goodrich & Rosati; Douglas Carsten – Wilson Sonsini Goodrich & Rosati; Art Dykhuis – Wilson Sonsini Goodrich & Rosati; Lora Green – Wilson Sonsini Goodrich & Rosati; Jeff Guise – Wilson Sonsini Goodrich & Rosati; Alina Litoshyk – Wilson Sonsini Goodrich & Rosati; Ellie Steiner – Wilson Sonsini Goodrich & Rosati; Richard Torczon – Wilson Sonsini Goodrich & Rosati; Lori Westin – Wilson Sonsini Goodrich & Rosati;

Law Firms: Weil, Gotshal & Manges; Wilson Sonsini Goodrich & Rosati;

Clients: Mylan, Inc.; Sanofi-Aventis SA ;